P

Prelude Therapeutics
D

PRLD

5.59000
USD
-0.87
(-13.47%)
مفتوح الان
حجم التداول
334
الربح لكل سهم
0
العائد الربحي
0
P/E
-1
حجم السوق
66,304,486
أصول ذات صلة
    P
    PRLD
    -0.87000
    (-13.47%)
    5.59000 USD
الأخبار المقالات

العنوان: Prelude Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.